DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

Claims for Patent: ► Subscribe

A pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The tablet is a matrix tablet and a single-dose administration of one or more tablets to a subject under fasted conditions provides a mean Cm.about. for each of the first active agent and the second active agent that is 70% to 135% of a respective mean Cm.about. provided by administering an immediate release oral dosage form to a subject under fasted conditions every 4 to 6 hours over a 12 hour time period, wherein cumulative dosage amounts administered over the 12 hour time period of each active agent is equivalent to the respective amount of each active agent in the pharmaceutical tablet.

1. A solid matrix tablet pharmaceutical composition consisting essentially of a monolithic extended release matrix having: 54 mg of codeine phosphate; 8 mg
chlorpheniramine maleate; 60 to 125 mg of hydroxypropyl methylcellulose; and one or more pharmaceutical processing aids, wherein the codeine phosphate and chlorpheniramine maleate are present as a homogenous admixture within the matrix.

2. The pharmaceutical composition of claim 1 wherein the hydroxypropyl methylcellulose is Hypromellose 2208 and is present in an amount of from 65 mg to 85 mg.

3. The pharmaceutical composition of claim 1 that has a release time of 25% of codeine and chlorpheniramine of from between 0.3 hours and 1.0 hours, a 50% release time of codeine and chlorpheniramine of from between 0.9 hours and 4.9 hours or a
75% release time of codeine and chlorpheniramine of from between 2.0 hours and 11.3 hours determined using a USP Type II (paddle) Dissolution Apparatus set at 50 rpm in about 900 mL of 0.1 N hydrochloric acid solution in water at about 37.degree. C.

5. The pharmaceutical composition of claim 4 having from 65 mg to 85 mg of a release rate controlling non-ionic oxyl-containing hydrophilic polymer which is hydroxypropyl methylcellulose.

6. The pharmaceutical composition of claim 4 that has a release time of 25% of codeine phosphate and chlorpheniramine maleate of from between 0.3 hours and 1.0 hours, a 50% release time of codeine phosphate and chlorpheniramine maleate of from
between 0.9 hours and 4.9 hours or a 75% release time of codeine phosphate and chlorpheniramine maleate of from between 2.0 hours and 11.3 hours determined using a USP Type II (paddle) Dissolution Apparatus set at 50 rpm in about 900 mL of 0.1 N
hydrochloric acid solution in water at about 37.degree. C.

7. The pharmaceutical composition of claim 4 which when placed in a USP Type II (paddle) Dissolution Apparatus at 50 rpm in 900 mL of 0.1 N hydrochloric acid solution in water at 37.degree. C. about 50% of the codeine phosphate is released
between 1.5 hours to 3 hours.

8. A single layer solid matrix tablet pharmaceutical composition comprising: codeine or a pharmaceutically acceptable salt thereof; chlorpheniramine or a pharmaceutically acceptable salt thereof; and 60 mg to 125 mg of a release rate
controlling non-ionic oxyl containing polymer and said composition substantially free of ionic polymer which when placed in a USP Type II Dissolution Apparatus at 50 rpm in 900 mL of 0.1 N hydrochloric acid solution in water at 37.degree. C. about 50%
of the codeine or pharmaceutically acceptable salt is released between 1.5 hours to 3 hours, wherein the codeine and chlorpheniramine are present as a homogenous admixture within the matrix.

9. The pharmaceutical composition of claim 8 which when placed in a USP Type II Dissolution Apparatus at 50 rpm in 900 mL of 0.1 N hydrochloric acid solution in water at 37.degree. C. the ratio of the amount of codeine or pharmaceutically
acceptable salt thereof released to the amount of chlorpheniramine or pharmaceutically acceptable salt thereof released at a single time point between 1 hour and 4 hours is from about 0.8:1 and about 1.2:1.

11. The pharmaceutical composition of claim 8 said codeine or pharmaceutically acceptable is 54 mg of codeine phosphate; said chlorpheniramine or pharmaceutically acceptable thereof is 8 mg of chlorpheniramine maleate; or said release rate
controlling non-ionic oxyl containing polymer is hydroxypropyl methylcellulose which is present in an amount of from 65 mg to 85 mg.

12. The pharmaceutical composition of claim 8 said codeine or pharmaceutically acceptable salt thereof is 54 mg of codeine phosphate.

13. The pharmaceutical composition of claim 8 said chlorpheniramine or pharmaceutically acceptable salt thereof is 8 mg of chlorpheniramine maleate.

14. A single layer tablet consisting of: (a) a first active agent which is codeine or a pharmaceutically acceptable salt thereof; (b) a second active agent which is chlorpheniramine or a pharmaceutically acceptable salt thereof; (c) a release
rate controlling non-ionic oxyl-containing hydrophilic polymer; and (d) one or more pharmaceutical processing aids, said single layer tablet when placed in a USP Type II Dissolution Apparatus at 50 rpm in 900 mL of 0.1 N hydrochloric acid solution in
water at 37.degree. C. about 50% of the codeine or pharmaceutically acceptable salt is released between 1.5 hours to 3 hours and said first active agent, said second active agent and said release rate controlling non-ionic oxyl-containing hydrophilic
polymer are present in amounts to provide therapeutically effective amounts of said first active agent and said second active agent sufficient for dosing to a human subject once every 12 hours wherein said first active agent and said second active agent
are in a homogenous admixture within said single layer tablet.

15. The single layer tablet of claim 14 said first active agent is 54 mg of codeine phosphate.

16. The single layer tablet of claim 14 said second active agent is 8 mg of chlorpheniramine maleate.

17. The single layer tablet of claim 14 wherein said release rate controlling non-ionic oxyl-containing hydrophilic polymer is hydroxypropyl methylcellulose which is present in an amount of from 60 mg to 125 mg.

18. The single layer tablet of claim 14 wherein the release rate controlling non-ionic oxyl-containing hydrophilic polymer is hydroxypropyl methylcellulose which is present in an amount of from 65 mg to 85 mg.

19. The single layer tablet of claim 14 which is substantially free of ionic polymer.

20. The single layer tablet of claim 14 wherein the hydroxypropyl methylcellulose has an average apparent viscosity of about 3000 cP to about 15000 cP when determined in a 2% solution in water at 20.degree. C.

21. The single layer tablet of claim 14 that has no food effect when administered to a human subject.

22. The single layer tablet of claim 14 which is resistant to alcohol associated dose dumping.

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.